Distal myopathy with rimmed vacuoles (DMRV)-hereditary inclusion body myopathy (hIBM) is an adult-onset, moderately progressive autosomal recessive myopathy; eventually, affected individuals become wheelchair bound 1 . It is characterized clinically by skeletal muscle atrophy and weakness, and pathologically by rimmed vacuoles, which are actually accumulations of autophagic vacuoles [2] [3] [4] , scattered angular fibers and intracellular accumulation of amyloid and other proteins 5 . To date, no therapy is available for this debilitating myopathy, primarily because the disease pathomechanism has been enigmatic. It is known that the disease gene underlying DMRV-hIBM is GNE, encoding glucosamine (UDP-N-acetyl)-2-epimerase and N-acetylmannosamine kinase 6-8 -two essential enzymes in sialic acid biosynthesis 9 . It is still unclear, however, whether decreased sialic acid production causes muscle degeneration, as GNE has been proposed to have roles other than for sialic acid biosynthesis [10] [11] [12] . By showing that muscle atrophy and weakness are completely prevented in a mouse model of DMRV-hIBM after treatment with sialic acid metabolites orally, we provide evidence that hyposialylation is indeed one of the key factors in the pathomechanism of DMRVhIBM. These results support the notion that DMRV-hIBM can potentially be treated simply by giving sialic acids, a strategy that could be applied in clinical trials in the near future.
Sialic acids are the most abundant terminal monosaccharides on glycoconjugates of eukaryotic cell surfaces and are involved in a variety of cellular functions 9 . As GNE enzymatic activity measured in vitro in cells transfected with mutated GNE constructs is reduced by 70-90% 13 , hyposialylation is thought to contribute to the pathogenesis of DMRV-hIBM 8, 13, 14 . The role of hyposialylation is further supported by the phenotype of the DMRV-hIBM mouse model, in which Gne-deficient mice transgenically express the human GNE gene with D176V mutation (Gne -/-hGNED176V-Tg) 15 . These mice show hyposialylation in various organs in addition to the characteristic features of muscle atrophy, weakness and degeneration and amyloid deposition. In these mice, hyposialylation is documented from birth 15 , yet they only develop muscle symptoms several weeks later, including decreased twitch force production in isolated muscles starting at 10 weeks of age and impairment of motor performance from 20 weeks of age onward 16 .
Addition of sialic acid metabolites has been shown to recover overall sialylation in cells 9, 13 . The challenge in administering sialic acid in vivo, however, is mainly its rapid excretion in the urine. After a single intraperitoneal injection of N-acetylneuraminic acid (NeuAc), the most abundant sialic acid, the sialic acid concentration in the serum is considerably increased within minutes ( Supplementary  Fig. 1a ,c online); but 90% of the sialic acid is found in the urine within 5-30 min, and almost all of it is excreted within 4 h ( Supplementary Fig. 1b,d) . After a single dose of NeuAc by the intragastric route, the sialic acid concentration in the serum is half that achieved by the intraperitoneal route, but the excretion rate is slower, as 70% of the sialic acid is found in the urine within 30-60 min ( Supplementary Fig. 1b,d ). We observed a similar pattern of excretion after a single dose of the physiological sialic acid precursor, N-acetylmannosamine (ManNAc) 17 ( Supplementary Fig. 1e,f) . These results suggest that NeuAc and ManNAc are rapidly excreted, and that the intragastric route may be more advantageous in increasing the serum abundance of sialic acid.
As ManNAc is converted to NeuAc after delivery into cells 18 , it is potentially a rich source of sialic acid in vivo. In the initial portion of this study, we evaluated the efficacy of ManNAc as a treatment for disease in four groups of DMRV-hIBM mice aged 5-6 weeks. At this age, the mice already have hyposialylation, but without obvious signs of myopathy 15 . The DMRV-hIBM mice received either water (control treatment; n ¼ 5) or ManNAc in their drinking water with an increasing dosing schedule (computed as mg per kg bodyweight per day): the low dose was 20 mg (n ¼ 5), the medium dose was 200 mg (n ¼ 4) and the high dose was 2,000 mg 19 (n ¼ 4). Equal numbers of unaffected littermates (whose genotypes are Gne +/-or Gne +/-hG-NED176V-Tg; we have previously shown that these mice do not have any symptoms 15 ) for each group were also treated (n ¼ 18). We treated mice continuously until 54-57 weeks of age and found an improvement in the survival of DMRV-hIBM mice, as compared to control treatment, in all treatment groups (Fig. 1a) , with a statistical trend favoring the medium-and high-dose groups, which both displayed 100% survival, over the low-dose group, which showed only a partial improvement in survival. Treatment lowered the serum creatine kinase concentration (Fig. 1b) and led to an increase in parameters assessing overall motor performance, including treadmill performance and endurance tests and a hanging test (Fig. 1c and Supplementary Fig. 2a,b online) . Likewise, treatment with ManNAc also increased body weight ( Supplementary Fig. 2c ) and muscle mass (Fig. 1d ) and led to a marked change in pathology (Fig. 1e) . Only one among the treated mice had rimmed vacuoles, and the number of rimmed vacuoles was significantly lower than that among mice who received control treatment (*P o 0.05). Treatment also increased muscle cross-sectional area (CSA) (Fig. 1f) and force production ( Fig. 1g and Supplementary Fig. 3a-d online) and substantially diminished congophilic, amyloid-positive and tau-positive inclusions (Fig. 1e) . One treated mouse in the low-dose group and one in the high-dose group showed intracellular amyloid deposits (data not shown). Of note, the number of deposits in these mice was notably lower than in control-treated mice. We did not observe expression of LC3 and Lamp2, which are markers for autophagosomal structures, in the muscle sections of treated mice, except for one mouse that had few rimmed vacuoles in the muscle ( Supplementary Fig. 4 online) . The favorable results in skeletal muscle parameter measurements were accompanied by an increase in sialic acid in the serum (Fig. 1h) and an increase in membrane-bound sialic acid in muscle (Fig. 1i ) and other organs ( Supplementary Fig. 5a online) . In addition to the considerable change in pathology, the number of rimmed vacuoles and intracellular amyloid inclusions was markedly reduced (Fig. 1j ). For all parameters tested, we did not observe dose dependence.
ManNAc was tolerated well by the treated mice, as kidney and liver function tests were normal (Supplementary Table 1 online). In the high-dose group, however, both of the female DMRV-hIBM mice in the group showed multiple ovarian masses after treatment (data not shown), suggesting a possible caveat in using high doses of ManNAc. Histopathological findings in these ovarian masses were akin to those of polycystic ovarian cysts, containing both hemorrhagic and fluidfilled cysts, in addition to hyperemia; on careful examination, we did not find any signs of malignancy (data not shown).
Because the 20-mg dose of ManNAc was effective in preventing the myopathic symptoms in majority of the DMRV-hIBM mice, we subsequently used this low dose in another cohort of mice to evaluate the efficacy of other metabolites. We gave four groups of 10-to 20-week-old DMRV-hIBM mice either ManNAc (n ¼ 6), NeuAc (n ¼ 5), sialic acid conjugate (sialyllactose, n ¼ 7) or water (as control treatment; n ¼ 10) continuously until 54-57 weeks of age. We 
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also treated equal numbers of littermate controls for each group (n ¼ 18). At 10-20 weeks of age, the DMRV-hIBM mice show only early reduction in production of force (detected by ex vivo analysis of muscle contractile properties), but no apparent muscle weakness, in addition to hyposialylation of most organs 16 . Thus, in this study, this treatment protocol is designed for the prevention of disease. Sialyllactose is a conjugated sialic acid that contains about 45% sialic acid. It is the major source of sialic acid in milk in addition to k-casein 20 . All agents were well tolerated at a dose of 20 mg per kg body weight per day (Supplementary Table 1 ). Treatment with any of the three sialic acid compounds improved the survival of the DMRV-hIBM mice versus the control-treated group, from a median survival at 54-57 weeks of 55.6% to one of 86.9%, and reduced the hazard ratio from 34.05 to 0.26 ( Fig. 2a) . Also, with treatment the body weight of treated DMRV-hIBM mice increased as compared to the controltreated group (Fig. 2b) . We next addressed the relationship between hyposialylation and the development of myopathic symptoms in DMRV-hIBM mice. After treatment, there was a modest increase in the serum sialic acid, but it was only significant in ManNAc-treated (P ¼ 0.038) and NeuActreated (P ¼ 0.001) groups (Fig. 2c) . In muscle (Fig. 2d ) and other organs ( Supplementary Fig. 5b ), there were considerably larger amounts of the bound forms of sialic acids in the three treatment groups as compared to the control-treated group.
Treated DMRV-hIBM mice performed better than control-treated mice in running on a treadmill (Fig. 2e) , enduring a specific running workload ( Supplementary Fig. 6a online) and holding on to an inverted mesh wire ( Supplementary Fig. 6b ). Overall, the motor performance of the treated DMRV-hIBM mice almost reached that achieved by nondiseased littermates and was paralleled by a decrease in serum creatine kinase values (Fig. 2f) . Previously, we showed that muscle weakness or decreased production of force is largely due to atrophy during the early stages of the disease and is compounded at the later stages by rimmed vacuole formation and muscle degeneration 21 . In the current study, treated mice showed an increase in weight (Fig. 3a) and CSAs of gastrocnemius and tibialis anterior muscles (Fig. 3b) . Furthermore, ex vivo measurement of force in isolated muscles showed a marked increase in both the specific isometric ( Fig. 3c ) and specific tetanic (Fig. 3d) forces in the gastrocnemius and tibialis anterior muscles (see Supplementary Fig. 7a ,b online) after treatment. Notably, although the twitch-tetanic ratio was increased in the gastrocnemius in older DMRV-hIBM mice 16 , it was significantly reduced only in NeuAc-treated (P o 0.05) and ManNAc-treated (P o 0.05) groups ( Supplementary Fig. 7c ).
The increase in force generation was proportional to the increase in muscle area but not to the number of fibers, suggesting that the increase in force production is probably due to an increase in singlefiber diameter, and this is exemplified by the smaller number of atrophic fibers in the gastrocnemius muscles of the three treatment groups (Fig. 3e,f ) when compared to control-treated mice. As we have previously implied 16 , atrophy in DMRV-hIBM mice seems to follow a mechanism distinct from the canonical pathways of atrophy in the muscle 21 . In DMRV-hIBM mice, because atrophy is prevented by increasing muscle sialylation, a causal relationship between hyposialylation and atrophic cascade is suggested.
Rimmed vacuoles and intracellular deposits presumably contribute to the loss of muscle power in DMRV-hIBM mice, especially as they age 16 . Rimmed vacuoles are most likely activated secondarily to cellular events such as protein misfolding or aggregation. Although all mice in the control-treated group showed rimmed vacuoles in the gastrocnemius, only a few in the treatment groups showed rimmed vacuoles (Fig. 4a) . In DMRV-hIBM mice, the chance of developing rimmed vacuoles was substantially lower after treatment with ManNAc (odds ratio, 1.8%), NeuAc (odds ratio, 2.2%) and sialyllactose (odds ratio, 1.3%) as compared to control treatment (100%). Likewise, in those treated mice that had rimmed vacuoles, the number of rimmed vacuoles was much smaller than in controltreated mice (Fig. 4b) . As rimmed vacuoles are autophagic in nature 2-4 , we checked for acid phosphatase staining and immunoreactivity to LC3 and Lamp2 and found decreased staining for these proteins (Fig. 4a) . The amounts of LC3-I and LC3-II, used as an index to analyze autophagic induction in tissues 22, 23 , were lower in the skeletal muscles after treatment ( Supplementary Fig. 8 online) .
In DMRV-hIBM mice, intracellular amyloid inclusions in muscles have been noted to occur earlier than rimmed vacuole formation 15 . We examined skeletal muscle cryosections and found out that only a few mice in the treatment groups showed such accumulations (Fig. 4a-c) , with the percentage of metabolite-treated mice having such inclusions being substantially lower than for the control-treated group. The chance of having amyloid accumulations is likewise lower in the treatment group: 1.3% for ManNAc, 1.6% for NeuAc and 0.9% for sialyllactose. To quantify the amount of amyloid burden in the muscle and plasma, we measured the amount of b-amyloid peptides 1-40 and 1-42, both of which accumulate in the muscles of DMRV-hIBM mice 15 , by ELISA in total muscle homogenate (Fig. 4d) and plasma (Fig. 4e) the same efficacy. Likewise, the amount of the C99 fragment of b-amyloid precursor protein was also decreased after treatment ( Supplementary Fig. 9 online) .
We also evaluated various proteins, such as phosphorylated tau 5 and polyubiquitinated proteins 24 , which are known to accumulate in muscles of DMRV-hIBM mice, and did not find immunoreactive signals for phosphorylated tau (Fig. 4e) or polyubiquitinated proteins (data not shown) after treatment.
Here we have shown that hyposialylation is one of the key factors in the pathomechanism of DMRV-hIBM. We have also provided evidence that prophylactic treatment with ManNAc, using three different doses, prevented the myopathic phenotype in the majority of the DMRV-hIBM mice and substantially reduced the number of rimmed vacuoles and amyloid accumulations in a few DMRV-hIBM mice. We did not observe dose-dependent efficacy when we compared all parameters, although the survival rate was better for the mediumand high-dose groups, and serum sialic acid was higher among those who received the high dose (Fig. 1e,i,j) . There is no straightforward explanation as to why we do not see a clear dose-dependent efficacy of ManNAc treatment in DMRV-hIBM mice. Taking the pharmacokinetic properties of NeuAc and ManNAc into consideration, it can be surmised that even if one gives a higher dose, not all of the metabolite administered through the oral route is delivered into the muscle. Alternatively, one may hypothesize that the muscle has some maximum limit for actually incorporating sialic acid, such that increasing the oral dose of metabolite would not be translated into increasing the sialic acid pool in muscle. However, more experiments are needed to clarify this issue, including the use of labeled sialic acid and tracing the amount incorporated (distribution) into the tissue to compare the different doses in vivo. The absence of a clear dose response is difficult to explain but may also imply a need for more sensitive methods in analyzing the molecular markers in DMRV-hIBM.
Our results suggest that increasing the sialylation status, at least in muscle, can prevent the development of the myopathic phenotype in the majority of treated DMRV-hIBM mice or at least delay the progression in the few DMRV-hIBM mice that eventually show some rimmed vacuoles in skeletal muscle, despite a marked improvement in muscle performance. The increase in sialic acid abundance in the muscle and various organs after oral administration of sialic acid metabolites is consistent with the increase in protein sialylation after ManNAc administration in the recently used mouse knock-in model of the GNE M712T mutation, in which the mice developed podocytopathy 19 . Although the role of amyloid deposition within the myofibers has not been clarified, it should be noted that sialic acid has some role in conferring stability on glycoproteins 25, 26 and might act as scavenger of radicals such as H 2 O 2 (ref. 27), both of which roles have been implicated in amyloidogenesis and hence could be affected when total sialic acid abundance is decreased in muscle. From our data, it can be surmised that correction of hyposialylation might reduce the amyloid burden in muscles. Nevertheless, this intracellular b-amyloid accumulation may be an epiphenomenon to hyposialylation, as amyloid deposition has been noted in a variety of myopathies 28, 29 . Recently, it has been demonstrated that neprilysin, a metallopeptidase b-amyloid precursor protein-processing enzyme, is hyposialylated and has reduced expression and enzymatic activity in hIBM muscles; this implies that hyposialylation might impair neprilysin and contribute to increased accumulation of b-amyloid peptides.
In conclusion, our results support the concept that hyposialylation in this myopathy should not be considered merely as a by-product of a metabolic impairment, but rather as one of the factors behind the pathomechanism of the disease. There are still several issues that need to be addressed, such as the absence of clear dose response efficacy to ManNAc and the role of sialic acid itself in muscle metabolism, and, more importantly, the therapeutic effect of sialic acid metabolites in DMRV-hIBM. Nevertheless, from our data we can conclude that replenishment of the total sialic acid in muscle by administering sialic acid precursor, sialic acid itself or sialic acid conjugate considerably prevents skeletal muscle atrophy, loss of power and myofiber degeneration in the DMRV-hIBM mouse model. More notably, our data corroborate the concept that DMRV-hIBM is a potentially treatable myopathy. Low-dose NeuAc, ManNAc and sialyllactose are effective in improving the sialylation status in the muscle and serum and may be considered in future clinical trials.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
ONLINE METHODS
Mice. All mouse protocols were approved by the Ethical Review Committee on the Care and Use of Rodents in the National Institute of Neuroscience, National Center of Neurology and Psychiatry. Generation of Gne -/-hG-NED176V-Tg (DMRV-hIBM) mice has been previously described 11 . For all experiments, we used data from littermate mice (Gne +/-hGNED176V-Tg, or wild-type) for comparison with DMRV-hIBM mice. We housed all animals mice in a barrier-protected facility that strictly adhered to specific pathogen-free-grade maintenance, and we maintained them on a 12-h to 12-h light-to-dark cycle with unlimited access to food and water. On average, an adult mouse takes about 14 mg per kg body weight per day of sialic acid from food.
Reagents. We purchased ManNAc and NeuAc from Japan Food and Liquor Alliance. Sialyllactose was from Sigma.
Treatment protocol. For ManNAc treatment, we grouped the DMRV-hIBM mice into four groups, and we gave them either water (control treatment) (n ¼ 5) or daily increasing doses of ManNAc (mg per kg body weight per day). The low dose was 20 mg (n ¼ 5), the medium dose was 200 mg (n ¼ 4) and the high dose was 2,000 mg (n ¼ 4). We also treated an equal number of littermates (n ¼ 18). We added ManNAc into the drinking water, and we computed the dose according to weight. We adjusted the concentration in drinking water every 4 d depending on the amount of water the mice could drink. We initiated treatment from 5 weeks of age and continued until the mice reached at least 55 weeks of age.
For low-dose therapy, we gave the DMRV-hIBM mice either 20 mg per kg body weight per day ManNAc (n ¼ 6), NeuAc (n ¼ 5), sialyllactose (n ¼ 7) or placebo (n ¼ 10). We also treated equal numbers of littermates for all experimental groups. We diluted the metabolites into the drinking water and adjusted the doses every 4 d, similarly to ManNAc treatment. We started treatment at 10-20 weeks of age and continued until the mice reached at least 55 weeks of age.
We collected blood from tail every month for creatine kinase measurement and toxicology tests. At the end of the experimental protocol, we measured the weight of the mice, anesthesized them and collected the gastrocnemius for analysis of contractile properties (see below). We then killed the mice and collected their other organs for analysis.
Analysis of motor performance and contractile properties of the muscle. We evaluated the motor performance and measured the contractile properties of the gastrocnemius and tibialis anterior muscles according to previous protocols 16, 30 (see Supplementary Methods online).
Morphological analysis. We prepared and stained muscle cryosections according to published protocols 15, 31 . We counted the number of rimmed vacuoles in six transverse 10 mmÀthick cryosections (at least 100 mm apart) stained with H&E on whole gastrocnemius sections for each group of mice.
For morphometric analyses, we stained sarcolemma of gastrocnemius muscle cryosections (see Supplementary Methods) and obtained six randomly selected digital images to evaluate single-fiber CSA as previously reported 16 .
Imunohistochemical analysis. We performed immunohistochemical analysis as described previously 15 (see Supplementary Methods).
Preparation of protein fractions for sialic acid measurement. We prepared crude membrane fractions as previously reported 32 (see Supplementary Methods).
Sialic acid measurement. We measured sialic acid concentration in the plasma and other organs as previously reported 15, 33 . We employed the same methodology in determining the kinetics of NeuAc. In the plasma, the sialic acid detected represented mostly sialic acid conjugates and was r1% free sialic acid.
Amyloid quantification. For quantifying the amount of amyloid in myofibers, we fixed six 10 mm-thick cryosections (each section was 100 mm apart) from the gastrocnemius muscle in paraformaldehyde for 30 min, followed by postfixation in ice-cold methanol. We immunostained sections with antibody to amyloid (clone 6E10, Covance) in a 1 in 400 dilution according to published protocols 15 . We counted as positive only signals within the myofibers in the whole gastrocnemius section.
We prepared samples for ELISA according to published protocols with slight modifications 34 . For western blotting to detect the c99 fragment of b-amyloid precursor protein with antibody to amyloid, we extracted protein by 2Â sample buffer containing 9.6% SDS, 4 M urea, 16% sucrose and 700 mM 2-mercaptoethanol, heated at 56 1C for 10 min. We resolved proteins by 10% bis-Tris (hydroxymethyl) methane SDS-PAGE (Invitrogen) under reducing conditions, transferred them to a nitrocellulose membrane and probed with antibody to b-amyloid (clone 6E10). For ELISA, we used the same method for protein homogenization, but we extracted protein using equal volumes of 0.4% diethylamine and 100 mM NaCl. We centrifuged samples at 100,000g for 1 h at 4 1C and pH-neutralized the supernatant with 0.5 M Tris base pH 6.8. We then used the supernatant for ELISA of b-amyloid 1-42 (Wako) and b-amyloid 1-40 (IBL) after brief vortexing. We normalized the amount of amyloid per mg protein. For plasma amyloid, we used 50 ml of thawed plasma.
Biochemical and toxicology assays. We measured serum creatine kinase as previously described 15 . We determined the activity of plasma alkaline phosphatase using the Japanese Society of Clinical Chemistry method 35 , with p-nitrophenylphosphate as substrate and ethylaminoethanol-HCl as buffer. We measured alanine transaminase by determining the reduction of NADH (Kyowa Medics). We assayed blood urea nitrogen by an automatic clinical analyzer (Dri-Chem 3,500 V, Fuji Film). We made all measurements three times.
Sialic acid and N-acetylmannosamine pharmacokinetics. See Supplementary Methods online.
Statistical analyses. All values are expressed as means ± s.e.m., except for single-fiber diameter, for which values are expressed as mean ± range. For survival analysis, we used the Kaplan-Meier method to draw the survival curve and used the log-rank test and the Gehan-Breslow-Wilcoxon test to compare groups. For other analysis to determine significance among groups, we used one-way analysis of variance with Dunnett's post-test to compare the treatment group with the placebo group. For the computation of odds ratio, we used Fisher's exact test. We set the level of significance to P o 0.05 for all analyses.
